Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC-MedSci.cn

Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC

Yu, HA; Baik, CS; Gold, K; Hayashi, H; Johnson, M; Koczywas, M; Murakami, H; Nishio, M; Steuer, C; Su, WC; Yang, J; Karam, S; Qi, Z; Qiu, Y; Chen, S; Yu, C; Janne, PA

ANNALS OF ONCOLOGY, 2020; 31 (): S1189

科室
- - 订阅+
  - 更多科室
工具
服务